A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

As the authors reported in Radiology Case Reports, the patient had no history of cancer and had no pain, weakness, numbness, ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...

During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, ...

C. Ola Landgren, MD, PhD, discusses the feedback he received on minimal residual disease at this year’s Miami Myeloma MRD ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Background: Multiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. This study aims to describe the ...

• Multiple sclerosis (MS) is a progressive, immune-mediated disorder where the system designed to keep your body healthy mistakenly attacks parts of your body that are not harmful, specifically ...

Multiple myeloma represents an unmet need, emphasizing the significance of continued research and development in this field. Treatment with cemsidomide resulted in notable responses at multiple dose ...